Serum Otoconin-90 and Otolin-1 Concentrations in Benign Paroxysmal Positional Vertigo.

Objective: The aim was to evaluate the value of otolith-associated protein otoconin-90 (OC90) and otolin-1 in the pathogenesis research and clinical treatment of benign paroxysmal positional vertigo (BPPV).

Material And Method: The study included 50 patients with BPPV admitted to neurology and otorhinolaryngology departments and 30 healthy subjects with no history of dizziness as a control group.

Results: BPPV and controls were similar in terms of gender and age.